J Cancer Prev.  2019 Jun;24(2):65-71. 10.15430/JCP.2019.24.2.65.

The Role of Peroxiredoxin Family in Cancer Signaling

Affiliations
  • 1Department of Health Sciences and Technology, Graduate School of Medicine, Gachon University, Incheon, Korea. hhjang@gachon.ac.kr
  • 2Department of Biochemistry, College of Medicine, Gachon University, Incheon, Korea.

Abstract

Peroxiredoxins (Prxs) are antioxidant enzymes that protect cells from oxidative stress by reducing intracellular accumulation of reactive oxygen species (ROS). In mammalian cells, the six Prx isoforms are ubiquitously expressed in diverse intracellular locations. They are involved in the regulation of various physiological processes including cell growth, differentiation, apoptosis, immune response and metabolism as well as intracellular ROS homeostasis. Although there are increasing evidences that Prxs are involved in carcinogenesis of many cancers, their role in cancer is controversial. The ROS levels in cancer cells are increased compared to normal cells, thus promoting cancer development. Nevertheless, for various cancer types, an overexpression of Prxs has been found to be associated with poor patient prognosis, and an increasing number of studies have reported that tumorigenesis is either facilitated or inhibited by regulation of cancer-associated signaling pathways. This review summarizes Prx isoforms and their basic functions, the relationship between the expression level and the physiological role of Prxs in cancer cells, and their roles in regulating cancer-associated signaling pathways.

Keyword

Peroxiredoxins; Oxidative stress; Cancer; Peroxidase activity; Tumorigenesis

MeSH Terms

Apoptosis
Carcinogenesis
Homeostasis
Humans
Metabolism
Oxidative Stress
Peroxiredoxins*
Physiological Processes
Prognosis
Protein Isoforms
Reactive Oxygen Species
Peroxiredoxins
Protein Isoforms
Reactive Oxygen Species
Full Text Links
  • JCP
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr